NCT06104644View on ClinicalTrials.gov

A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

Active, not recruitingOBSERVATIONAL
Enrollment

550

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

August 29, 2025

Study Completion Date

May 31, 2030

Conditions
Plaque Psoriasis
Interventions
DRUG

Deucravacitinib

Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics

Trial Locations (2)

56242

Local Institution - 0001, Selters

Unknown

Dermatologische Spezial- und Schwerpunktpraxis Selters, Selters

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06104644 - A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany | Biotech Hunter | Biotech Hunter